Calithera is developing small molecule drugs that slow tumor growth by controlling key metabolic pathways. Our investigational onco-metabolism drugs take advantage of specific metabolic requirements of tumor cells and cancer-fighting immune cells. Calithera is currently evaluating telaglenastat, a glutaminase inhibitor, in two randomized renal cell carcinoma trials in combination with standard of care therapies, and in other solid tumors trials. Calithera is also developing an oral arginase inhibitor, an oral small molecule CD73 inhibitor and a pipeline of novel tumor metabolism candidates.